



(51) International Patent Classification:

C12N 15/62 (2006.01) A61K 39/215 (2006.01)
C12N 15/85 (2006.01) A61K 39/295 (2006.01)
C12N 7/00 (2006.01) C07K 14/005 (2006.01)
A61K 39/00 (2006.01) A61K 31/7088 (2006.01)
A61K 39/12 (2006.01) A61P 31/14 (2006.01)
A61K 39/145 (2006.01)

(21) International Application Number:

PCT/US2022/034104

(22) International Filing Date:

17 June 2022 (17.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/211,974	17 June 2021 (17.06.2021)	US
63/240,278	02 September 2021 (02.09.2021)	US
63/275,398	03 November 2021 (03.11.2021)	US

(71) Applicant: **ELIXIRGEN THERAPEUTICS, INC.**
[US/US]: 855 North Wolfe Street, Suite 624, Baltimore,
Maryland 21205 (US).

(72) Inventor: **KO, Minoru S., H.;** c/o Elixirgen Therapeutics,
Inc., 855 North Wolfe Street, Suite 624, Baltimore, Mary-
land 21205 (US).

(74) Agent: **LEKUTIS, Christine** et al.; Morrison & Foerster
LLP, 425 Market Street, San Francisco, California 94105
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES




FIG. 1

(57) Abstract: The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a coronavirus nucleocapsid protein or an influenza virus nucleocapsid protein in operable combination with a mammalian signal peptide. The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding other viral nucleocapsid protein(s) in operable combination with a mammalian signal peptide. The RNA constructs are suitable for active immunization against a virus in a mammalian subject, such as a human subject.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*